Proteins related to proliferation and survival such as LCK, AMPK and CYCLIN E were found to be hyperactivated or overexpressed in poor prognosis patients with BCP-ALL, and could represent new molecular drug targets in pediatric B-ALL. This evidence concerns the gene PRKAA1 and precursor B-cell acute lymphoblastic leukemia.